Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Ravaud

Showing results (21-30 of 221) with videos related to

Pageof 23
Sort By:
Cancer Treatment Reviews|February 5, 2013
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implicationsRomano Danesi, Joseph P Boni, Alain Ravaud
Current Urology Reports|December 6, 2011
Targeted therapies in metastatic renal cell carcinoma: overview of the past yearMarine Gross-Goupil, Christophe Massard, Alain Ravaud
Current Opinion in Urology|August 2, 2008
Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathwaysHervé Wallerand, Robert R Reiter, Alain Ravaud
Current Opinion in Urology|July 21, 2010
Bladder cancer in patients after organ transplantationHervé Wallerand, Alain Ravaud, Jean-Marie Ferrière
Seminars in Oncology|August 27, 2013
Combination therapy in metastatic renal cell cancerAlain Ravaud, Marine Gross-Goupil, Joaquim Bellmunt
Oral Oncology|January 15, 2019
Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case reportAmaury Daste, Laurence Digue, Alain Ravaud, et al.
Expert Opinion on Investigational Drugs|August 11, 2012
Lapatinib and renal cell carcinomaMarine Gross-Goupil, Jean-Christophe Bernhard, Alain Ravaud
Bulletin Du Cancer|July 5, 2020
Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAveMarine Gross-Goupil, Charlotte Domblides, Felix Lefort, et al.
Bulletin Du Cancer|April 24, 2012
[Strategy in advanced castration-resistant prostate cancer]Marine Gross-Goupil, Sophie Roca, Gilles Pasticier, et al.
Clinical Medicine Insights. Oncology|November 20, 2013
Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinomaMarine Gross-Goupil, Louis François, Amandine Quivy, et al.
Pageof 23

Showing results (21-30 of 221) with videos related to

Sort By:
Pageof 23
Cancer Treatment Reviews|February 5, 2013
Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implicationsRomano Danesi, Joseph P Boni, Alain Ravaud
Current Urology Reports|December 6, 2011
Targeted therapies in metastatic renal cell carcinoma: overview of the past yearMarine Gross-Goupil, Christophe Massard, Alain Ravaud
Current Opinion in Urology|August 2, 2008
Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathwaysHervé Wallerand, Robert R Reiter, Alain Ravaud
Current Opinion in Urology|July 21, 2010
Bladder cancer in patients after organ transplantationHervé Wallerand, Alain Ravaud, Jean-Marie Ferrière
Seminars in Oncology|August 27, 2013
Combination therapy in metastatic renal cell cancerAlain Ravaud, Marine Gross-Goupil, Joaquim Bellmunt
Oral Oncology|January 15, 2019
Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case reportAmaury Daste, Laurence Digue, Alain Ravaud, et al.
Expert Opinion on Investigational Drugs|August 11, 2012
Lapatinib and renal cell carcinomaMarine Gross-Goupil, Jean-Christophe Bernhard, Alain Ravaud
Bulletin Du Cancer|July 5, 2020
Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAveMarine Gross-Goupil, Charlotte Domblides, Felix Lefort, et al.
Bulletin Du Cancer|April 24, 2012
[Strategy in advanced castration-resistant prostate cancer]Marine Gross-Goupil, Sophie Roca, Gilles Pasticier, et al.
Clinical Medicine Insights. Oncology|November 20, 2013
Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinomaMarine Gross-Goupil, Louis François, Amandine Quivy, et al.
Pageof 23